Case Report: Efficacy of Disitamab Vedotin (RC-48) in HER2-Low Metastatic Breast Cancer

A 14.7 KB document details a single case report of a 40-year-old woman with heavily pretreated HER2-low metastatic breast cancer. The report, authored by Ruiyue Wu and last updated in May 2026, describes treatment with the antibody-drug conjugate disitamab vedotin (RC-48), noting a time to treatment failure of 4.6 months and overall survival of 13.7 months post-treatment initiation.

Use Cases

• Analyzing the clinical response to a novel antibody-drug conjugate based on the detailed case description of tumor regression and biomarker changes.
• Studying the dynamic nature of HER2 status in metastatic disease based on the report of status changes from diagnosis through progression.
• Evaluating real-world treatment timelines and outcomes for later-line therapies based on the reported time to treatment failure and survival data.

Strengths

• Provides specific clinical metrics, including a time to treatment failure of 4.6 months and a survival period of 13.7 months.
• Offers a detailed narrative on a single patient's disease course, treatment response, and HER2 status evolution.
• Document is shared under a permissive CC-BY-4.0 license.

Limitations

• Row count is unknown, which may limit suitability assessment; the dataset is a single case report document.
• Column-level documentation is absent; field semantics must be inferred after download.
• The findings are based on a single patient case, limiting generalizability.

Provenance

Source

Ruiyue Wu via figshare

Collection Method

Clinical case report documentation.

Time Range

Covers the treatment and follow-up period for a single patient case.

Freshness

Last updated 2026-05-04 04:16:47; freshness should be verified.

Geography

Likely China, as the report discusses the first China-developed anti-HER2 ADC.